

# Evaluate CDMO Intelligence for Pharma

**Understand the complex Contract Development  
and Manufacturing Organization (CDMO) landscape.  
Secure the best-fit vendors ahead of the competition.**



The pharmaceutical CDMO market is holding strong, forecast to grow 7.29% annually until 2028. To secure an edge, it's crucial for pharma companies to forge strategic partnerships with the right CDMOs early on.

**Does your organisation have the insights to understand contract manufacturing challenges for pipeline drugs well enough in advance?**

**Often, the information available barely scratches the surface, making assessments of CDMOS a challenge. It also impacts your ability to make accurate drug volume forecasts and to align mid-term revenue projections.**

## **This is where Evaluate CDMO Intelligence steps in**

Use our time-saving intelligence tool to select the right vendor at the right time. Profile and compare candidates, speed up your projects, and make confident decisions in an evolving CDMO segment.

### **HOW WE HELP:**



Effortlessly profile vendors, compare their strengths and weaknesses, and pinpoint those with the expertise to provide top-quality service.



Access a pool of high-performing vendors that can accelerate your project timelines, reducing the need for lengthy RFIs or RFPs.



Negotiate contracts that are cost-effective without compromising the quality of service you require.



Identify potential competitors, gain insights into their existing relationships, and understand their preferred vendor technologies and ROAs.

### **EVALUATE EQUIPS YOU TO:**



Project revenue with leading drug sales forecasting.



Predict regulatory success through machine learning.



Assess demand with one-of-a-kind drug volume forecasts.

**Evaluate**

a norstella company

**We're here to help you succeed.**

Get in touch to discuss how to harness our game-changing CDMO Intelligence for pharmaceutical companies.

[info@evaluate.com](mailto:info@evaluate.com) | [www.evaluate.com](http://www.evaluate.com)

Evaluate HQ: +44-(0)20-7377-0800 | Evaluate Americas: +1-617-573-9450 | Evaluate APAC: +81-(0)80-1164-4754